{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:26:20Z","timestamp":1785590780725,"version":"3.56.0"},"reference-count":24,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Xenobiotica"],"published-print":{"date-parts":[[2021,4,3]]},"DOI":"10.1080\/00498254.2020.1839983","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T15:40:35Z","timestamp":1603208435000},"page":"251-261","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Assessment of the <i>in vitro<\/i> cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic"],"prefix":"10.1080","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-5251","authenticated-orcid":false,"given":"Rajesh","family":"Chavan","sequence":"first","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Zope","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Chavan","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-1303","authenticated-orcid":false,"given":"Kiran","family":"Patil","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-4259","authenticated-orcid":false,"given":"Ravindra","family":"Yeole","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5943-5031","authenticated-orcid":false,"given":"Sachin","family":"Bhagwat","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5128-4061","authenticated-orcid":false,"given":"Mahesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"CIT0001","unstructured":"Advanced Life Sciences, 2009. FDA briefing document: cethromycin tablets. Available from: www.accessdata.fda.gov"},{"key":"CIT0003","unstructured":"Bayer HealthCare Pharmaceuticals Inc. 2010. Highlights of prescribing Information: AVELOX (moxifloxacin hydrochloride) Film coated tablet, injection, solution for IV use. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label"},{"key":"CIT0004","unstructured":"Bayer HealthCare Pharmaceuticals Inc., 2016. Highlights of prescribing Information: CIPRO (ciprofloxacin hydrochloride) tablet for oral use, oral suspension. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label"},{"key":"CIT0005","unstructured":"BGP Pharma ULC, 2016. Product monograph: BIAXIN (clarithromycin for oral suspension USP 125\u2009mg\/5\u2009mL and 250\u2009mg\/5\u2009mL). Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label"},{"key":"CIT0006","unstructured":"Cempra Pharmaceuticals Inc. 2016. FDA briefing document: solithromycin for CABP. Available from: www.accessdata.fda.gov"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1356"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2020.1756007"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2001.0070s3011.x"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.083832"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.137"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42051-x"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01230-17"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01253-19"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04652-14"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01994-13"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.2174\/157488406775268183"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.038596"},{"key":"CIT0021","unstructured":"Pfizer Canada Inc. 2012. Prescribing information: ERYC (Erythromycin delayed release capsules USP). Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label"},{"key":"CIT0022","unstructured":"Pfizer Canada Inc. 2013. Product monograph: ZITHROMAX (azithromycin dihydrate Tablets 250\u2009mg, 500\u2009mg and 600\u2009mg. Powder for Oral Suspension 100\u2009mg\/5\u2009mL and 200\u2009mg\/5\u2009mL USP. For Injection 500\u2009mg per vial (100\u2009mg\/mL) Intravenous Infusion after reconstitution. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01096-17"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.500"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.6.639"},{"key":"CIT41838228","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.2.267"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00261.x"}],"container-title":["Xenobiotica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00498254.2020.1839983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T01:07:09Z","timestamp":1620608829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00498254.2020.1839983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4,3]]}},"alternative-id":["10.1080\/00498254.2020.1839983"],"URL":"https:\/\/doi.org\/10.1080\/00498254.2020.1839983","relation":{},"ISSN":["0049-8254","1366-5928"],"issn-type":[{"value":"0049-8254","type":"print"},{"value":"1366-5928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}